Rapid diagnostic HCV antibody assays

Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA. .
Antiviral therapy (Impact Factor: 3.14). 01/2012; 17(7 Pt B):1409-13. DOI: 10.3851/IMP2470
Source: PubMed

ABSTRACT Approximately 4.1 million Americans have been infected with HCV and 45-85% of chronically infected persons are unaware of their status. Rapid anti-HCV assays can assist and expedite the identification of those unaware of their infection. Performance characteristics of pre-market rapid anti-HCV assays (Chembio, MedMira and OraSure) have been evaluated. Their sensitivity (78.9-99.3%) and specificity (80-100%) varied. Future investigations could include evaluation of rapid anti-HCV tests in persons who are coinfected with HCV and HIV, and development of rapid HCV-antigen tests and nucleic acid tests.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pakistan is among the countries with high prevalence rates of Hepatitis B and C virus infections. Proper diagnosis of the disease is very crucial in combating with the high prevalence rates in a country. In Pakistan, numbers of diagnostic tests like Immuno-chromatography technique (ICT), enzyme linked immuno-sorbent assay (ELISA) and polymerase chain reaction (PCR) are in use to demonstrate the presence of hepatitis in the subjects. In the present study, we used ICT, ELISA and PCR techniques and compared the sensitivity and specificity of these techniques in order to evaluate best suited method for local situations. Sensitivity analysis of these tests has shown that ICT has a low detection rate of positive cases in comparison with the ELISA and PCR based nucleic acid detection techniques. We suggest that ELISA and PCR should be used instead of ICT for screening purposes in hospitals, blood banks and diagnostic laboratories.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent approvals of direct-acting, orally delivered pharmaceuticals for the treatment of patients with infection by HCV and of a point-of-care assay for community screening of HCV infection have generated impetus to widen the identification of HCV-infected individuals. Diagnosis of HCV infection is, however, still based on the detection of anti-HCV immunoglobulin G. As treatment is intended for individuals with current infection, testing for evidence of infection would need to centre on the detection of HCV viraemia. Minimizing the complexity and costs associated with HCV nucleic acid testing and speeding the development and validation of HCV antigen assays expedite the identification of HCV-viraemic individuals. Establishing means to diagnose recent HCV infection and to engage in surveillance of drug-resistant HCV are also apposite. Successful implementation of these various measures brightens prospects for the eventual elimination of HCV.
    Antiviral therapy 01/2012; 17(7 Pt B):1391-5. DOI:10.3851/IMP2468 · 3.14 Impact Factor


Available from
Jun 3, 2014